Monday, October 21, 2019

// // Leave a Comment

Takeda picks up Cour's celiac treatment, promising $420M in biobucks

Cour Pharma's pipeline is based on the work of Stephen Miller, Ph.D., a professor of microbiology and immunology at Northwestern University. (Cour Pharma). Share Facebook Twitter LinkedIn Email Print. As John Puisis was building a biotech company ...

from Google Alert - health https://ift.tt/2MArJXH
via IFTTT

0 comments:

Post a Comment